Determination of the HER2 status in BC is a clinical routine that uses a combination of immunohistochemistry (IHC) to evaluate HER2 protein expression levels and in situ hybridization (ISH) to assess HER2 gene status [6, 7]. Here, ERBB2 is linked to breast cancer.